MSD announces new regional president amid COVID-19 research
MSD, a trade name of US-based biopharmaceutical company Merck & Co., Inc., have revealed a new President for its Human Health Division in Asia Pacific: David Peacock, appointed from February 1, 2022. David brings a broad range of experience and perspectives to MSD from previous senior roles in the UK, US, and across Asia.
“I am excited to return to Asia, a diverse and vibrant region,” David enthused. “Asia also presents some of the world’s toughest healthcare challenges, and I am looking forward to working with our teams to build on existing partnerships and establishing new ones so that our innovative medicines and vaccines reach as many patients as possible.”
MSD has a wide footprint in Singapore, bringing together all its business divisions ranging from Manufacturing, Research and Development, Human Health’s commercial operations, Animal Health, an IT Hub and MSD Asia Pacific Regional Headquarters. MSD in Asia Pacific has approximately 6,000 employees across 12 key markets.
MSD is focused on the discovery and development of innovative medicines and vaccines and are working to enable access to these medical inventions to improve population health, to save and improve lives – the most recent being the progress of its oral antiviral COVID-19 treatment, molnupiravir.
MSD has confirmed active and consistent antiviral activity of molnupiravir against the SARS-CoV-2 variant Omicron in vitro. The findings were pooled from multiple studies in six countries, proving the potential of molnupiravir as an important treatment option for certain adults with mild to moderate COVID-19.
